TherapeuticsMD, Inc. 2025 Annual Report: Major Highlights, Risks, and Shareholder Considerations

Executive Summary

TherapeuticsMD, Inc. (“TherapeuticsMD” or “the Company”) has released its 2025 Annual Report, presenting a comprehensive update following its strategic transformation into a pharmaceutical royalty company. The report details significant changes in the Company’s business model, financial health, operational risks, and key shareholder issues that may have material implications for share value.

Key Business Developments

• Strategic Shift: In December 2022, TherapeuticsMD transitioned from a women’s healthcare operating company to a pharmaceutical royalty company. The Company now derives its revenues primarily from royalties on products licensed to third-party pharmaceutical organizations, notably Mayne Pharma.
• Business Model: The Company no longer conducts commercial operations but instead collects royalties on licensed products. As of the report date, revenues are highly dependent on the performance of licensees, with three primary licensees contributing to revenue streams.
• Minimal Internal Operations: As of December 31, 2025, the Company employs only one full-time executive, with operational support provided primarily by external consultants.
• Liquidity and Going Concern: The Company’s financial position raises substantial doubt about its ability to continue as a going concern, with the latest audit opinion including an explanatory paragraph to that effect. The Company reported \$7.5 million in cash and cash equivalents at year-end 2025 but faces uncertainty regarding the sufficiency of its resources.
• Outstanding Shares and Ownership: As of March 30, 2026, there were 11,574,362 shares of common stock outstanding. Rubric Capital Management LP and its affiliates hold approximately 25.5% of the common stock, giving them significant influence over corporate decisions.

Financial and Operational Risks

• Revenue Concentration: All revenues stem from royalties. Any failure by licensees to sustain or increase product sales could materially impact the Company’s financial position and growth prospects.
• Dependence on Licensees: The Company is reliant on third-party performance for milestone achievements and product sales. Any operational, regulatory, or commercial setbacks affecting licensees are likely to have a direct adverse impact on TherapeuticsMD.
• Liquidity Concerns and Capital Needs: The Company may be forced to raise additional capital via equity or debt offerings. Such actions could dilute existing shareholders and/or introduce unfavorable terms. Failure to secure new financing could force asset sales, business combination transactions, or even discontinuation of operations.
• Potential Nasdaq Delisting: Following the business change, the Company may be treated as a “public shell” under Nasdaq rules. Delisting from the Nasdaq Global Select Market is a risk, which could reduce liquidity, institutional interest, and negatively affect the stock price.
• Significant Management Turnover: The Company has undergone executive transition, including the termination of most top executives post-transaction and the appointment of a new Chief Executive Officer and Principal Financial and Accounting Officer. Such transitions can disrupt company operations and strategic continuity.
• Sublease Liabilities: The Company subleases its former headquarters to third parties, potentially exposing it to liabilities and losses related to those arrangements.
• Nasdaq Listing Requirements: Failure to maintain Nasdaq listing requirements could trigger delisting proceedings. If delisted, shares could trade OTC (“Pink Sheets”), with reduced investor protections, governance standards, and market visibility.
• Substantial Net Operating Loss Carryforwards: The Company has approximately \$584.6 million in federal NOL carryforwards, which may be limited in use by Section 382 of the Internal Revenue Code, pending future profitability.
• Control by Principal Stockholder: Rubric Capital’s significant ownership allows it to exert substantial control over board appointments and major corporate actions, which may not always align with the interests of minority shareholders.
• Exploration of Strategic Alternatives: The Company is actively evaluating potential strategic transactions, including mergers, acquisitions, or business combinations. The outcomes and value to shareholders remain uncertain.
• No Dividends Anticipated: The Company does not expect to pay cash dividends in the foreseeable future. Shareholder returns will be tied solely to stock price appreciation.

Potential Share Price Moving Issues

• Going Concern and Liquidity Risks: The explicit going concern warning, coupled with the possibility of asset sales, business combinations, or equity dilution, are highly material and could significantly affect valuation.
• Dependence on Licensee Performance and Ongoing Litigation: Revenue concentration and disputes with Mayne Pharma (including pending lawsuits) are critical. Adverse rulings or underperformance by licensees could materially impact royalty streams and financial results.
• Nasdaq Delisting Risk: Potential loss of Nasdaq listing could reduce trading liquidity, limit institutional investment, and negatively affect the share price.
• Strategic Alternatives: The ongoing review of strategic alternatives may result in significant transactions that could re-rate the Company’s valuation, either positively or negatively.
• Control Issues: The outsized influence of a single shareholder (Rubric Capital) could affect strategic direction and the likelihood of takeover or other value-creating events.

Other Shareholder Considerations

• Intellectual Property Risks: The business relies on the strength of its IP portfolio and the performance of licensees in protecting and commercializing these assets. Disputes or failures in IP management could have material adverse effects.
• No Key Person Insurance: With only one employee and a reliance on consultants, the Company lacks “key person” insurance, increasing operational vulnerability.
• Tax Law Changes and Compliance: New or changing tax regulations could impact the Company’s net operating losses and overall tax position.
• Market Volatility: The Company’s shares may experience high volatility due to its business transition, financial uncertainty, and small market capitalization, leading to potential large moves on news or rumors.

Conclusion

The 2025 Annual Report for TherapeuticsMD, Inc. discloses a challenging operational and financial environment. Investors should be aware of substantial going concern risks, high dependency on licensee performance, the possibility of share dilution or asset sales, and the risk of Nasdaq delisting. Ongoing litigation, strategic alternatives, and the influence of a single major shareholder may all have significant impacts on the share price in the near and medium term.

Investors are strongly advised to review the full set of risk factors and monitor developments closely.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with financial or legal advisers before making investment decisions.

View TherapeuticsMD, Inc. Historical chart here